1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Pandemic Influenza - Pipeline Review, H1 2015

Pandemic Influenza - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 135 pages

Pandemic Influenza - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Pandemic Influenza - Pipeline Review, H1 2015’, provides an overview of the Pandemic Influenza’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Pandemic Influenza, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pandemic Influenza and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pandemic Influenza
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pandemic Influenza and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pandemic Influenza products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pandemic Influenza pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pandemic Influenza
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pandemic Influenza pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Pandemic Influenza - Pipeline Review, H1 2015
Table of Contents
Introduction 7
Global Markets Direct Report Coverage 7
Pandemic Influenza Overview 8
Therapeutics Development 9
Pipeline Products for Pandemic Influenza - Overview 9
Pipeline Products for Pandemic Influenza - Comparative Analysis 10
Pandemic Influenza - Therapeutics under Development by Companies 11
Pandemic Influenza - Therapeutics under Investigation by Universities/Institutes 15
Pandemic Influenza - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Pandemic Influenza - Products under Development by Companies 19
Pandemic Influenza - Products under Investigation by Universities/Institutes 22
Pandemic Influenza - Companies Involved in Therapeutics Development 23
AIMM Therapeutics B.V. 23
AltraVax Inc. 24
AmVac AG 25
Big DNA Ltd. 26
BioDiem Ltd 27
Celltrion, Inc. 28
Cilian AG 29
Codagenix, Inc. 30
ContraFect Corporation 31
Emergent BioSolutions Inc. 32
GlaxoSmithKline plc 33
Hemispherx Biopharma, Inc. 34
Immunovaccine, Inc. 35
Johnson and Johnson 36
Medicago Inc. 37
NanoBio Corporation 38
Novartis AG 39
Novavax, Inc. 40
OPKO Health, Inc. 41
PDS Biotechnology Corporation 42
PeptiVir, Inc. 43
Protein Sciences Corporation 44
Sinovac Biotech Ltd. 45
Sirnaomics, Inc. 46
TaiGen Biotechnology Co., Ltd. 47
TechnoVax, Inc. 48
Theraclone Sciences, Inc. 49
TSRL, Inc. 50
UMN Pharma Inc. 51
VaxInnate Corporation 52
Pandemic Influenza - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Combination Products 54
Assessment by Target 55
Assessment by Mechanism of Action 57
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
A-06 - Drug Profile 63
Alferon LDO - Drug Profile 64
AMV-411 - Drug Profile 65
BDNA-002 - Drug Profile 66
Bispecific Monoclonal Antibody to Inhibit Hemagglutinin for Seasonal and Pandemic Influenza - Drug Profile 67
CF-404 - Drug Profile 68
CiFlu - Drug Profile 69
CTP-25 - Drug Profile 71
CTP-27 - Drug Profile 72
flu pandemic (H5N1) vaccine - Drug Profile 73
IKT-041 - Drug Profile 74
influenza (H5) vaccine - Drug Profile 75
influenza [H7N9] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 76
influenza [strain H5N1] (monovalent) vaccine - Drug Profile 77
influenza [strain H7N9] (monovalent) vaccine - Drug Profile 78
influenza vaccine - Drug Profile 80
influenza vaccine - Drug Profile 81
influenza vaccine - Drug Profile 82
influenza vaccine - Drug Profile 83
Monoclonal Antibodies to Inhibit Hemagglutinin for Pandemic Influenza - Drug Profile 84
Monoclonal Antibodies to Inhibit Hemagglutinin for Seasonal Influenza and Pandemic Influenza - Drug Profile 85
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 86
MVAH-5HA - Drug Profile 87
pandemic infleunza vaccine - Drug Profile 88
pandemic influenza [H5N1] vaccine - Drug Profile 89
pandemic influenza [H7N9] (monovalent) vaccine - Drug Profile 90
pandemic influenza vaccine - Drug Profile 91
pandemic influenza vaccine - Drug Profile 92
pandemic influenza vaccine - Drug Profile 93
pandemic influenza vaccine - Drug Profile 94
pandemic influenza vaccine - Drug Profile 95
pandemic influenza vaccine - Drug Profile 96
pandemic influenza vaccine [H5N1] - Drug Profile 97
PDS-0102 - Drug Profile 98
PVI-1000 - Drug Profile 99
Small Molecules for Influenza - Drug Profile 100
Small Molecules for Influenza - Drug Profile 101
Small Molecules for Pandemic Influenza - Drug Profile 102
STP-702 - Drug Profile 103
TCN-032 - Drug Profile 104
TSR-026 - Drug Profile 106
TSR-462 - Drug Profile 107
TVX-002 - Drug Profile 108
UMN-0501 - Drug Profile 109
UMN-0901 - Drug Profile 111
VAX-161 - Drug Profile 112
VAX-16101C - Drug Profile 113
VX-787 - Drug Profile 114
Pandemic Influenza - Recent Pipeline Updates 115
Pandemic Influenza - Dormant Projects 124
Pandemic Influenza - Discontinued Products 126
Pandemic Influenza - Product Development Milestones 127
Featured News and Press Releases 127
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 131
Disclaimer 132

List of Tables

Number of Products under Development for Pandemic Influenza, H1 2015 12
Number of Products under Development for Pandemic Influenza - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 15
Number of Products under Development by Companies, H1 2015 (Contd..1) 16
Number of Products under Development by Companies, H1 2015 (Contd..2) 17
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Development, H1 2015 20
Comparative Analysis by Unknown Stage Development, H1 2015 21
Products under Development by Companies, H1 2015 22
Products under Development by Companies, H1 2015 (Contd..1) 23
Products under Development by Companies, H1 2015 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2015 25
Pandemic Influenza - Pipeline by AIMM Therapeutics B.V., H1 2015 26
Pandemic Influenza - Pipeline by AltraVax Inc., H1 2015 27
Pandemic Influenza - Pipeline by AmVac AG, H1 2015 28
Pandemic Influenza - Pipeline by Big DNA Ltd., H1 2015 29
Pandemic Influenza - Pipeline by BioDiem Ltd, H1 2015 30
Pandemic Influenza - Pipeline by Celltrion, Inc., H1 2015 31
Pandemic Influenza - Pipeline by Cilian AG, H1 2015 32
Pandemic Influenza - Pipeline by Codagenix, Inc., H1 2015 33
Pandemic Influenza - Pipeline by ContraFect Corporation, H1 2015 34
Pandemic Influenza - Pipeline by Emergent BioSolutions Inc., H1 2015 35
Pandemic Influenza - Pipeline by GlaxoSmithKline plc, H1 2015 36
Pandemic Influenza - Pipeline by Hemispherx Biopharma, Inc., H1 2015 37
Pandemic Influenza - Pipeline by Immunovaccine, Inc., H1 2015 38
Pandemic Influenza - Pipeline by Johnson and Johnson, H1 2015 39
Pandemic Influenza - Pipeline by Medicago Inc., H1 2015 40
Pandemic Influenza - Pipeline by NanoBio Corporation, H1 2015 41
Pandemic Influenza - Pipeline by Novartis AG, H1 2015 42
Pandemic Influenza - Pipeline by Novavax, Inc., H1 2015 43
Pandemic Influenza - Pipeline by OPKO Health, Inc., H1 2015 44
Pandemic Influenza - Pipeline by PDS Biotechnology Corporation, H1 2015 45
Pandemic Influenza - Pipeline by PeptiVir, Inc., H1 2015 46
Pandemic Influenza - Pipeline by Protein Sciences Corporation, H1 2015 47
Pandemic Influenza - Pipeline by Sinovac Biotech Ltd., H1 2015 48
Pandemic Influenza - Pipeline by Sirnaomics, Inc., H1 2015 49
Pandemic Influenza - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 50
Pandemic Influenza - Pipeline by TechnoVax, Inc., H1 2015 51
Pandemic Influenza - Pipeline by Theraclone Sciences, Inc., H1 2015 52
Pandemic Influenza - Pipeline by TSRL, Inc., H1 2015 53
Pandemic Influenza - Pipeline by UMN Pharma Inc., H1 2015 54
Pandemic Influenza - Pipeline by VaxInnate Corporation, H1 2015 55
Assessment by Monotherapy Products, H1 2015 56
Assessment by Combination Products, H1 2015 57
Number of Products by Stage and Target, H1 2015 59
Number of Products by Stage and Mechanism of Action, H1 2015 61
Number of Products by Stage and Route of Administration, H1 2015 63
Number of Products by Stage and Molecule Type, H1 2015 65
Pandemic Influenza Therapeutics - Recent Pipeline Updates, H1 2015 118
Pandemic Influenza - Dormant Projects, H1 2015 127
Pandemic Influenza - Dormant Projects (Contd..1), H1 2015 128
Pandemic Influenza - Discontinued Products, H1 2015 129

List of Figures

Number of Products under Development for Pandemic Influenza, H1 2015 12
Number of Products under Development for Pandemic Influenza - Comparative Analysis, H1 2015 13
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 18
Comparative Analysis by Clinical Stage Development, H1 2015 19
Comparative Analysis by Early Stage Products, H1 2015 20
Assessment by Monotherapy Products, H1 2015 56
Number of Products by Top 10 Targets, H1 2015 58
Number of Products by Stage and Top 10 Targets, H1 2015 59
Number of Products by Top 10 Mechanism of Actions, H1 2015 60
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 60
Number of Products by Top 10 Routes of Administration, H1 2015 62
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 62
Number of Products by Top 10 Molecule Types, H1 2015 64
Number of Products by Stage and Top 10 Molecule Types, H1 2015 64

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

Influenza Diagnostics Market By Test Type, By End Use and Segment Forecasts to 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

H1N1 (Swine Influenza)- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s H1N1 (Swine Influenza) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

Influenza Diagnostics Market By Test Type (Rapid Influenza Diagnostic Test [RIDT], Reverse Transcription Polymerase Chain Reaction[RT-PCR], Cell Culture, Others - Immunofluorescence, Serology), By End Use, And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

The influenza diagnostics market is expected to reach USD 3.3 billion by 2024, according to a new report by Grand View Research, Inc. Influenza, or "the flu," is an infectious disease and affects the uppe ...


Download Unlimited Documents from Trusted Public Sources

Infectious Disease Statistics in the US

  • December 2016
    32 pages
  • Infectious Dise...  

    Asthma  

  • United States  

View report >

The future of the Vaccine Industry in the UK

  • December 2016
    2 pages
  • Vaccine  

    Infectious Dise...  

  • United Kingdom  

View report >

Infectious Disease Statistics in Brazil

  • December 2016
    9 pages
  • Infectious Dise...  

    Hospital  

  • Brazil  

View report >

Related Market Segments :

Influenza
Vaccine
Therapy
Biotechnology

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.